November 24, 2016 - By Nellie Frank · 0 Comments
Becton Dickinson & Co (NYSE:BDX) institutional sentiment increased to 0.9 in Q2 2016. Its up 0.01, from 0.89 in 2016Q1. The ratio is positive, as 339 funds started new and increased positions, while 382 cut down and sold their stock positions in Becton Dickinson & Co. The funds in our partner’s database now possess: 178.24 million shares, down from 179.07 million shares in 2016Q1. Also, the number of funds holding Becton Dickinson & Co in their top 10 positions increased from 42 to 51 for an increase of 9. Sold All: 50 Reduced: 332 Increased: 276 New Position: 63.
Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company has a market cap of $34.96 billion. The Firm operates through two business divisions: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. It has a 37.43 P/E ratio.
The stock increased 0.48% or $0.81 on November 23, hitting $168.48. About 1.10M shares traded hands. Becton Dickinson and Co (NYSE:BDX) has risen 5.38% since April 22, 2016 and is uptrending. It has underperformed by 0.03% the S&P500.
Analysts await Becton Dickinson and Co (NYSE:BDX) to report earnings on February, 1. They expect $2.12 earnings per share, up 8.16% or $0.16 from last year’s $1.96 per share. BDX’s profit will be $439.91 million for 19.87 P/E if the $2.12 EPS becomes a reality. After $2.12 actual earnings per share reported by Becton Dickinson and Co for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BD’s operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.”
Caledonia Investments Plc holds 7.03% of its portfolio in Becton Dickinson and Co for 110,800 shares. Jensen Investment Management Inc owns 2.26 million shares or 5.96% of their US portfolio. Moreover, Troy Asset Management Ltd has 5.31% invested in the company for 587,700 shares. The France-based Comgest Global Investors S.A.S. has invested 5.09% in the stock. Fundsmith Llp, a United Kingdom-based fund reported 1.79 million shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 5 insider sales for $10.28 million net activity.
Ratings analysis reveals 40% of Becton Dickinson’s analysts are positive. Out of 10 Wall Street analysts rating Becton Dickinson, 4 give it “Buy”, 1 “Sell” rating, while 5 recommend “Hold”. The lowest target is $146 while the high is $195. The stock’s average target of $166.67 is -1.07% below today’s ($168.48) share price. BDX was included in 16 notes of analysts from August 7, 2015. The rating was maintained by UBS on Friday, August 5 with “Buy”. RBC Capital Markets maintained the shares of BDX in a report on Thursday, February 4 with “Sector Perform” rating. The stock of Becton Dickinson and Co (NYSE:BDX) has “Neutral” rating given on Thursday, November 12 by Citigroup. The firm has “Buy” rating by Argus Research given on Wednesday, August 19. The stock of Becton Dickinson and Co (NYSE:BDX) earned “Neutral” rating by Citigroup on Thursday, February 4. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, August 7. On Monday, August 10 the stock rating was maintained by Deutsche Bank with “Hold”. The firm earned “Hold” rating on Wednesday, January 6 by Evercore. The company was upgraded on Thursday, February 11 by Deutsche Bank. The rating was downgraded by Citigroup to “Sell” on Friday, September 23.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Firm operates through two business divisions: BD Medical and BD Life Sciences. The Firm sells its products outside the United States, including hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; pharmacy automation equipment; respiratory equipment and disposable products; BD Vacutainer brand blood collection products; diagnostic systems and laboratory equipment and products, and flow cytometry instruments and reagents. The Firm has its manufacturing activities outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain and the United Kingdom.
More important recent Becton Dickinson and Co (NYSE:BDX) news were published by: Prnewswire.com which released: “Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt …” on November 16, 2016, also Nasdaq.com published article titled: “Becton, Dickinson and Company to boost quarterly dividend”, Reuters.com published: “BRIEF-Becton, Dickinson and Co announces tender offers for outstanding debt …” on November 16, 2016. More interesting news about Becton Dickinson and Co (NYSE:BDX) was released by: Seekingalpha.com and their article: “Becton, Dickinson & Co. (BDX) Q4 2016 Results – Earnings Call Transcript” with publication date: November 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank